Fig. 1From: Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled dataChange from baseline in HbA1c at week 26. a History of CV disease, b history of hypertension, c baseline statin use, d number of CV risk factors. CV cardiovascular, LS least squares, SE standard error, CI confidence interval, PBO placebo, CANA canagliflozinBack to article page